PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,555,629 | -30.2% | 50,705 | -8.8% | 0.00% | -33.3% |
| Q2 2023 | $2,227,451 | -4.3% | 55,589 | -2.5% | 0.00% | 0.0% |
| Q1 2023 | $2,327,109 | +4.3% | 57,023 | -1.4% | 0.00% | -25.0% |
| Q4 2022 | $2,232,083 | -26.4% | 57,811 | +1.3% | 0.00% | -20.0% |
| Q3 2022 | $3,034,000 | -9.6% | 57,043 | -0.9% | 0.01% | 0.0% |
| Q2 2022 | $3,357,000 | -22.6% | 57,575 | +1.4% | 0.01% | -16.7% |
| Q1 2022 | $4,335,000 | +16.8% | 56,798 | -7.9% | 0.01% | +50.0% |
| Q4 2021 | $3,711,000 | +11.3% | 61,667 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $3,333,000 | -8.7% | 59,510 | -1.1% | 0.00% | -20.0% |
| Q2 2021 | $3,651,000 | -19.0% | 60,171 | -6.4% | 0.01% | -16.7% |
| Q1 2021 | $4,507,000 | +16.8% | 64,297 | -0.3% | 0.01% | +20.0% |
| Q4 2020 | $3,859,000 | +1.1% | 64,491 | +1.6% | 0.01% | -16.7% |
| Q3 2020 | $3,817,000 | +16.8% | 63,487 | +1.9% | 0.01% | 0.0% |
| Q2 2020 | $3,268,000 | +56.4% | 62,288 | 0.0% | 0.01% | +50.0% |
| Q1 2020 | $2,089,000 | -26.3% | 62,288 | -0.5% | 0.00% | -20.0% |
| Q4 2019 | $2,836,000 | +17.9% | 62,597 | -0.9% | 0.01% | 0.0% |
| Q3 2019 | $2,406,000 | -11.4% | 63,196 | +1.2% | 0.01% | 0.0% |
| Q2 2019 | $2,716,000 | +16.8% | 62,441 | +2.2% | 0.01% | 0.0% |
| Q1 2019 | $2,325,000 | -13.6% | 61,094 | -2.3% | 0.01% | -16.7% |
| Q4 2018 | $2,690,000 | -10.2% | 62,521 | +2.6% | 0.01% | 0.0% |
| Q3 2018 | $2,994,000 | +53.0% | 60,925 | -0.2% | 0.01% | +50.0% |
| Q2 2018 | $1,957,000 | +3.8% | 61,072 | +0.8% | 0.00% | 0.0% |
| Q1 2018 | $1,886,000 | -33.3% | 60,559 | -2.2% | 0.00% | -33.3% |
| Q4 2017 | $2,828,000 | +19.8% | 61,947 | -1.5% | 0.01% | +20.0% |
| Q3 2017 | $2,361,000 | -28.9% | 62,886 | -9.6% | 0.01% | -28.6% |
| Q2 2017 | $3,319,000 | +1.3% | 69,576 | -3.1% | 0.01% | 0.0% |
| Q1 2017 | $3,275,000 | +35.0% | 71,816 | -4.4% | 0.01% | +40.0% |
| Q4 2016 | $2,426,000 | -8.2% | 75,116 | -2.7% | 0.01% | 0.0% |
| Q3 2016 | $2,642,000 | +2.5% | 77,216 | +1.0% | 0.01% | -16.7% |
| Q2 2016 | $2,578,000 | -37.2% | 76,416 | -1.3% | 0.01% | -33.3% |
| Q1 2016 | $4,104,000 | -20.8% | 77,457 | +14.8% | 0.01% | -30.8% |
| Q4 2015 | $5,183,000 | +89.8% | 67,498 | +1.6% | 0.01% | +85.7% |
| Q3 2015 | $2,731,000 | -42.0% | 66,458 | -0.2% | 0.01% | -36.4% |
| Q2 2015 | $4,707,000 | -18.8% | 66,558 | +2.0% | 0.01% | -21.4% |
| Q1 2015 | $5,797,000 | -1.6% | 65,242 | -1.8% | 0.01% | 0.0% |
| Q4 2014 | $5,891,000 | -7.7% | 66,442 | +0.9% | 0.01% | -12.5% |
| Q3 2014 | $6,383,000 | +6.8% | 65,861 | +1.2% | 0.02% | +6.7% |
| Q2 2014 | $5,979,000 | +70.5% | 65,087 | +29.9% | 0.02% | +66.7% |
| Q1 2014 | $3,506,000 | +22.2% | 50,087 | +0.4% | 0.01% | +12.5% |
| Q4 2013 | $2,868,000 | +20.3% | 49,887 | +0.6% | 0.01% | +14.3% |
| Q3 2013 | $2,385,000 | +71.2% | 49,587 | +3.3% | 0.01% | +40.0% |
| Q2 2013 | $1,393,000 | +50.6% | 48,024 | +49.9% | 0.01% | +66.7% |
| Q1 2013 | $925,000 | – | 32,044 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |